ISSN 1662-4009 (online)

Previous issue | Volume 17 | ESPEYB17 | Next issue

Yearbook of Paediatric Endocrinology 2020

ey0017.12-12 | Hyperlipidemia | ESPEYB17

12.12. GPR146 Deficiency protects against hypercholesterolemia and atherosclerosis

H Yu , A Rimbert , AE, et al. Palmer

To read the full abstract: Cell. 2019;179(6):1276–88 e14. doi: 10.1016/j.cell.2019.10.034Short summary: Deficiency in the orphan G protein coupled receptor 146 (GPR146) decreases blood lipid levels and protects against atherosclerosis in mice, independent of LDL receptor activity.Comment: Monogenic hypercholesterolemia is a heterogeneous gro...

ey0017.12-13 | Hyperlipidemia | ESPEYB17

12.13. 20-Year Follow-up of statins in children with familial hypercholesterolemia

IK Luirink , A Wiegman , DM, et al. Kusters

To read the full abstract: N Engl J Med. 2019;381(16):1547–56. doi: 10.1056/NEJMoa1816454Short summary: Twenty years of treatment of statin therapy in children with Familial Hypercholesterolemia (FH) slowed the progression of carotid intima–media thickness and reduced the risk of cardiovascular disease in adulthood. By age 39 years, the cumulative incidence of cardiovascul...

ey0017.12-14 | Hyperlipidemia | ESPEYB17

12.14. Statins for children with familial hypercholesterolemia

A Vuorio , J Kuoppala , PT, et al. Kovanen

To read the full abstract: Cochrane Database Syst Rev. 2019;2019(11). doi: 10.1002/14651858.CD006401.pub5Short summary: This systematic review shows that statin treatment is an effective lipid-lowering therapy in children with Familial Hypercholesterolemia (FH). Few or no safety issues were identified.Comment: Cochrane is an international cha...

ey0017.12-15 | Hyperlipidemia | ESPEYB17

12.15. Inclisiran for the treatment of heterozygous familial hypercholesterolemia

FJ Raal , D Kallend , KK, et al. Ray

To read the full abstract: N Engl J Med. 2020;382(16):1520–30. doi: 10.1056/NEJMoa1913805Short summary: Inclisiran (a small interfering double-stranded RNA against PCSK9) is superior to placebo in reducing LDL-C among individuals with heterozygous Familial Hypercholesterolemia who are already on statins and ezetimibe.Comment: Proprotein convertas...

ey0017.12-16 | Hyperlipidemia | ESPEYB17

12.16. Identification of ALK in thinness

M Orthofer , A Valsesia , R, et al. Magi

To read the full abstract: Cell. 2020. doi: 10.1016/j.cell.2020.04.034Short summary: In this study, rather than focusing on genes associated with obesity, the authors studied genetic variants associated with thinness (BMI <6th percentile for age). In a genome-wide association study from the Estonian Biobank, 881 people were classified as thin, and 3173 individuals with norm...

ey0017.12-17 | Hyperlipidemia | ESPEYB17

12.17. Working 9 to 5, not the way to make an academic living: Observational analysis of manuscript and peer review submissions over time

A Barnett , I Mewburn , S Schroter

To read the full abstract: BMJ. 2019;367:l6460. doi: 10.1136/bmj.l6460Short summary: There is wide variation around the world in how researchers manage their work-life balance.Comment: The Christmas edition of The BMJ published this observational study that examined more than 49 000 manuscripts and 76 000 peer review online submissions to The...